ERG induces taxane resistance in castration-resistant prostate cancer - Wikidata - awgldk - TriplyDB

ERG induces taxane resistance in castration-resistant prostate cancer

ERG induces taxane resistance in castration-resistant prostate cancer

http://www.wikidata.org/entity/Q30602046

about

Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Targeting the adaptive molecular landscape of castration-resistant prostate cancer Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.Chemotherapy in Prostate Cancer.Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.Molecular biomarkers to guide precision medicine in localized prostate cancer.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.The evolution of chemotherapy for the treatment of prostate cancer.Ethnicity and ERG frequency in prostate cancer.The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.Current treatment strategies for advanced prostate cancer.Pathology and molecular updates in tumors of the prostate: towards a personalized approach.The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer.Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.Genetics and biology of prostate cancer Chemotherapy and radiation for prostate cancer Improving adenoviral vectors and strategies for prostate cancer gene therapy

P2860

Q26796704-0F20B9F9-35E6-4FAA-9A33-DB7C27F51DEE Q27022821-D9203C80-F388-499D-9610-C939ABA50231 Q28117805-555EAFA5-8F13-4161-8ED1-7BAFB07878B2 Q30244818-5FE94F8B-9E03-434E-82C1-6BDB08DF6B2E Q35856517-1362D8EA-7F12-4C0E-97AF-2929FB3DAB80 Q36035812-C4CB234C-6080-4380-8014-887A9E3946FA Q36407003-C496CAB9-AE9D-4203-A840-67507D82E6A9 Q36586089-C517717D-7C5C-43CF-BD73-D2C19EE0565A Q38540198-D622DB8E-5398-4AAC-9CBA-2968AADA9042 Q38555599-33C452FB-7687-4EB3-B64D-953980395765 Q38607675-617BAD96-0FDA-4F6E-8A90-D2BCB43B091C Q38668635-DDB241D9-3ADA-4ED3-9729-4D3373B9BE88 Q38983790-5930368E-D203-499D-BDA5-A533DE0CF4F1 Q41839242-69EA5A1C-1B8A-4735-A080-FF8038BFD6B0 Q42335698-01BCEF1D-7534-4B1A-B43E-025B694CED8B Q45943517-1BF2FF5A-622D-4CBD-B945-B8AF61B14A09 Q46504038-A7BFA090-9024-40C6-BAD8-DFFF274622BB Q47273298-798E031A-0E01-4490-800B-9B6074F0C4C9 Q48087902-C00D0601-5049-4FD0-A4B6-86174A3D558A Q48561494-E9C7AB9F-C42F-47C0-A2B4-9ED37A5070C4 Q52861100-21CC7D89-AF19-45EB-96FB-825F8217A640 Q53527594-7EB2C0D1-1198-45CC-807B-E1B9E84354E3 Q53735518-E6AF6E61-F408-4B43-BAFF-7F3FC5E88194 Q54474207-33BDBA19-633C-4561-986F-5859A2843792 Q57106917-8D2C8F69-B48A-44F5-ADA3-FFDABB25C0D2 Q57112428-BD565EB2-C90C-4373-9057-FD39703EB512 Q58801177-C7A89B8F-BD06-40FB-BC7E-CF7290452447

P2860

ERG induces taxane resistance in castration-resistant prostate cancer

http://www.wikidata.org/entity/Q30602046

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

ERG induces taxane resistance in castration-resistant prostate cancer

@ast

ERG induces taxane resistance in castration-resistant prostate cancer

@en

type

label

ERG induces taxane resistance in castration-resistant prostate cancer

@ast

ERG induces taxane resistance in castration-resistant prostate cancer

@en

prefLabel

ERG induces taxane resistance in castration-resistant prostate cancer

@ast

ERG induces taxane resistance in castration-resistant prostate cancer

@en

P1433

Q30602046-3AE56F30-4DBC-4535-AEB9-E6DC7387840B

P1476

Q30602046-726D9283-BB52-49D7-9133-BC305DC339D3

P2093

Q30602046-03A215CB-3E19-4397-A058-C9CB5AC570A3

Q30602046-0C66A5CA-E4B5-4C1D-B173-A2A7DC318E50

Q30602046-2386E89D-44CF-4685-86C4-FC9D7CBD90C4

Q30602046-25D42E1B-A18E-4370-996F-F57652F0D172

Q30602046-2675B8FC-A81F-4A85-9441-5A9E5B05CA7B

Q30602046-2A64F025-084E-42B2-9303-E4E804836B09

Q30602046-62D1EFFD-8DFE-47D4-8ECF-BC941DE9A4F7

Q30602046-7967FBC1-4D21-4B22-9F4E-5A56410633EA

Q30602046-839030B5-42FC-4D0D-87FB-41AFD8E331E2

Q30602046-9366F7CF-0C99-4017-95ED-36BE45B7100B

P2860

Q30602046-01735540-8ACE-4FD4-96D9-B176D9479E54

Q30602046-037EE8AA-7390-4FDC-92E4-244BA8A8BCE2

Q30602046-03A3EB44-463E-4D62-B782-26AE82C1C550

Q30602046-0E6BF428-97DE-4DDF-9322-0826F1D6D359

Q30602046-0FEC599B-42DD-4634-AE7F-D85F227379AC

Q30602046-1B68EA97-384D-4C5D-A877-E77736BAF364

Q30602046-1B95C483-B78C-419A-9F2E-507B2D96931F

Q30602046-1D654C78-2948-4244-80F6-736A9FB4C13D

Q30602046-240B1E9B-00A7-4BB4-8D6F-0972F58AF571

Q30602046-2BA660FC-1DC4-4D0F-926E-98A174EAA62E

P2888

Q30602046-125E456C-3A9B-46C7-8BF9-37C7D7156AD8

P304

Q30602046-655F619D-4E4D-464D-AD63-A05BDC23777A

P31

Q30602046-7FB23BA1-F9C8-44A7-9436-489D1E94C254

P356

Q30602046-88FF13AA-9761-4AE4-9600-4E5C41F58673

P407

Q30602046-1863F93A-2BBC-4444-BD7D-D190E07E7C75

P478

Q30602046-69F5E1F0-F144-414B-92BA-6083015D41EB

P50

Q30602046-2BFEBC93-A197-406A-B730-D55B282ED597

Q30602046-85D214B7-5CC7-44DA-83A4-C25C260D443A

Q30602046-B8FAA1A2-C0E9-435E-B9C6-81B35629D2DE

Q30602046-C9B27338-642A-4CA4-B252-82CF43AC5C3E

Q30602046-CC4E7682-8AE0-4141-BC51-A7D13DACA52B

P577

Q30602046-57187706-C4CE-4EF7-B28B-88B04632C9D3

P5875

Q30602046-235A5333-3F2A-405F-A046-1BE9B6B6080C

P6179

Q30602046-6A396C34-46D6-4E0C-966C-112C69BA8228

P698

Q30602046-40C649EE-8452-4E78-BD5C-C4F4DFD8382C

P932

Q30602046-11088283-FCB2-420A-B7EA-AABEBFC777F3

P356

P1433

Nature Communications

P1476

ERG induces taxane resistance in castration-resistant prostate cancer

@en

P2093

Alexandre Matov

http://www.w3.org/2001/XMLSchema#string

Cynthia Cheung

http://www.w3.org/2001/XMLSchema#string

David M Nanus

http://www.w3.org/2001/XMLSchema#string

David S Rickman

http://www.w3.org/2001/XMLSchema#string

Giuseppe Galletti

http://www.w3.org/2001/XMLSchema#string

Himisha Beltran

http://www.w3.org/2001/XMLSchema#string

Jacqueline Fontugne

http://www.w3.org/2001/XMLSchema#string

Juan Miguel Mosquera

http://www.w3.org/2001/XMLSchema#string

Matthew Sung

http://www.w3.org/2001/XMLSchema#string

Sandra O'Toole

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis of microtubule plus end tracking by XMAP215, CLIP-170, and EB1

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics

The genomic complexity of primary human prostate cancer

The mutational landscape of prostate cancer

Structure of the alpha beta tubulin dimer by electron crystallography

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

Microtubules as a target for anticancer drugs

P2888

P304

5548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS6548

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Paraskevi Giannakakou

P577

2014-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268879352

http://www.w3.org/2001/XMLSchema#string

P6179

1052565764

http://www.w3.org/2001/XMLSchema#string

P698

25420520

http://www.w3.org/2001/XMLSchema#string

P932

4244604

http://www.w3.org/2001/XMLSchema#string